NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Additionally, PS has demonstrated efficacy against imatinib-resistant chronic myeloid leukemia (CML) cells both in vitro and in vivo by inhibiting NF-κB and Bcr-Abl, key factors in the development of resistance [46].